Background: The PANSS (Positive and Negative Syndrome Scale) is one of the most important rating instruments for patients with schizophrenia. Nevertheless, there is a long and ongoing debate in ...

Neurocrine has commenced a Phase III registrational programme to assess NBI-1117568 as a treatment for schizophrenia in adult ...

However, the number didn’t reach statistical significance. PANSS is a clinician-administered tool used to assess schizophrenia symptoms. Approved by the FDA to treat schizophrenia in September ...

The results show that the therapy failed to meet the threshold for statistical significance for the primary endpoint of change in the Positive and Negative Syndrome Scale (PANSS) total score.

Background Non-adherence to antipsychotic medication in schizophrenic patients is common and associated with symptom relapse and poorer long-term outcomes. The risk factors for treatment non ...

It appears shareholders were spooked by the size of the reduction in PANSS – a 7.5 improvement on placebo and an 18.2-point fall from baseline – compared to similarly-acting rival therapies in ...

APD = Antipsychotic background drug; PANSS = Positive and Negative Syndrome Scale; PSP = Personal and Social Performance Scale; CGI-S = Clinical Global Impressions Severity Scale; mITT = modified ...

Results from the study showed that KarXT demonstrated a statistically significant and clinically meaningful 9.6-point reduction in the Positive and Negative Syndrome Scale (PANSS) total score ...

ARISE trial showed a 2-point PANSS reduction with Cobenfy adjunctive therapy, but it missed statistical significance (P = 0.11). FDA approved Cobenfy in Sept. 2024; global schizophrenia sales ...

In the Phase 3 trial, adjunctive Cobenfy treatment demonstrated a 2.0-point reduction in the Positive and Negative Syndrome Scale (PANSS) total score compared to placebo with an atypical ...